Literature DB >> 16257280

Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese.

H Lynn1, T Kwok, S Y S Wong, J Woo, P C Leung.   

Abstract

Hypertension and osteoporosis are two major chronic diseases affecting the elderly. A cross-sectional study of 3887 Chinese men (n = 1958) and women (n = 1929) was used to explore the association between angiotensin converting enzyme inhibitor (ACEI) use and bone mineral density (BMD). The participants were aged 65 years and above, and were recruited using a combination of private solicitation and public advertising from community centers, housing estates, and the general community in Hong Kong. Demographic, medical, and lifestyle information was obtained from face to face interviews using standardized questionnaire, and physical examination measurements included anthropometry, tibial, and brachial systolic blood pressures, femoral neck, total hip, and lumbar spine BMD. In multiple regression analyses, after adjusting for age, weight, height, thiazide, beta-blocker, calcium channel blocker, statin, corticosteroid, and calcium supplement use, history of diabetes, heart disease, peripheral vascular disease, cigarette smoking, alcohol intake, and physical activity level, ACEI use was associated with higher femoral neck BMD (+0.015 g/cm2, P = 0.035) in women, and higher femoral neck (+0.015 g/cm2, P = 0.017), total hip (+0.016 g/cm2, P = 0.021), and lumbar spine (+0.043 g/cm2, P < 0.001) BMD in men. Thiazide use was associated with higher BMD at all three sites in general, although associations with BMD increase at the total hip (P = 0.07) and femoral neck (P = 0.09) were weak in men. Calcium channel blocker use was only significantly associated with BMD increase at the lumbar spine (P = 0.03) in women, and beta-blocker use did not have significant associations with BMD at any site. This study suggests that in addition to thiazide diuretics ACEI may have possible benefits in treating not only hypertension but also osteoporosis among older Chinese.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257280     DOI: 10.1016/j.bone.2005.09.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  46 in total

1.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Luca Carta; Jason R Cook; Silvia Smaldone; Gabriella Siciliano; Aaron N Rifkin; Harry C Dietz; Daniel B Rifkin; Francesco Ramirez
Journal:  Hum Mol Genet       Date:  2010-09-24       Impact factor: 6.150

2.  Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.

Authors:  Nahid Rianon; Catherine G Ambrose; Hannah Pervin; Melissa Garcia; Scherezade K Mama; Ann V Schwartz; Brendan Lee; Tamara Harris
Journal:  Arch Osteoporos       Date:  2017-10-28       Impact factor: 2.617

3.  Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice.

Authors:  Masao Kakoki; Kelli A Sullivan; Carey Backus; John M Hayes; Sang Su Oh; Kunjie Hua; Adil M H Gasim; Hirofumi Tomita; Ruriko Grant; Sarah B Nossov; Hyung-Suk Kim; J Charles Jennette; Eva L Feldman; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 4.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

5.  The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.

Authors:  L D Carbone; S Vasan; R L Prentice; G Harshfield; B Haring; J A Cauley; K C Johnson
Journal:  Osteoporos Int       Date:  2019-06-17       Impact factor: 4.507

6.  Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts.

Authors:  Yu Yu Liu; Wei Min Yao; Tie Wu; Bi Lian Xu; Fang Chen; Liao Cui
Journal:  J Bone Miner Metab       Date:  2010-08-06       Impact factor: 2.626

7.  A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.

Authors:  Monica Ibañez; Ana M Ortiz; Isabel Castrejón; J Alberto García-Vadillo; Inmaculada Carvajal; Santos Castañeda; Isidoro González-Alvaro
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

8.  Genetic determinants of osteoporosis: common bases to cardiovascular diseases?

Authors:  Francesca Marini; Maria Luisa Brandi
Journal:  Int J Hypertens       Date:  2010-03-25       Impact factor: 2.420

9.  The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese.

Authors:  Ya-Feng Zhang; Ling Qin; Ping-Chung Leung; Timothy C Y Kwok
Journal:  J Bone Miner Metab       Date:  2012-06-29       Impact factor: 2.626

Review 10.  Heart failure as a risk factor for osteoporosis and fractures.

Authors:  Aloice O Aluoch; Ryan Jessee; Hani Habal; Melinda Garcia-Rosell; Rehan Shah; Guy Reed; Laura Carbone
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.